Squarepoint
OVID icon

Squarepoint’s Ovid Therapeutics OVID Stock Holding History

Squarepoint’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$617K Buy
247,799
+228,862
+1,209% +$599K ﹤0.01% 3210
2026
Q2 		$50.9K Sell
18,937
-179,034
-90% -$462K ﹤0.01% 4268
2026
Q1 		$439K Buy
197,971
+158,937
+407% +$284K ﹤0.01% 3408
2025
Q4 		$63.6K Sell
39,034
-75,889
-66% -$117K ﹤0.01% 4105
2025
Q3 		$149K Sell
114,923
-106,203
-48% -$92K ﹤0.01% 4026
2025
Q2 		$72.9K Sell
221,126
-44,365
-17% -$13.4K ﹤0.01% 4245
2025
Q1 		$82.8K Buy
+265,491
New +$163K ﹤0.01% 4268
2024
Q2 		– Sell
-68,343
Closed -$208K – 4497
2024
Q1 		$208K Buy
68,343
+56,962
+501% +$191K ﹤0.01% 3593
2023
Q4 		$36.6K Buy
+11,381
New +$38.9K ﹤0.01% 3876
2023
Q2 		– Sell
-11,271
Closed -$29.1K – 3884
2023
Q1 		$29.1K Buy
+11,271
New +$26.7K ﹤0.01% 3103
2022
Q3 		– Sell
-10,543
Closed -$23K – 3311
2022
Q2 		$23K Buy
+10,543
New +$25.5K ﹤0.01% 2766
2021
Q3 		– Sell
-37,797
Closed -$148K – 3288
2021
Q2 		$148K Buy
+37,797
New +$149K ﹤0.01% 2932
2021
Q1 		– Sell
-70,987
Closed -$164K – 3490
2020
Q4 		$164K Sell
70,987
-69,731
-50% -$325K ﹤0.01% 2586
2020
Q3 		$808K Buy
+140,718
New +$942K 0.01% 1104
2020
Q2 		– Sell
-11,553
Closed -$34K – 2441
2020
Q1 		$34K Sell
11,553
-14,476
-56% -$48.8K ﹤0.01% 1749
2019
Q4 		$108K Buy
+26,029
New +$82.2K ﹤0.01% 2334
2018
Q3 		– Sell
-14,700
Closed -$115K – 2157
2018
Q2 		$115K Buy
+14,700
New +$126K ﹤0.01% 1630

Other funds holding OVID

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.4B AUM 32.2% 1-Year Est. Return

Squarepoint's OVID Position: Q3 2026 in Review

Squarepoint increased its Ovid Therapeutics (OVID) stake by 1,209% in Q3 2026, buying an estimated $599K and bringing the position to 247,799 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #3210.

Squarepoint first reported a position in OVID in Q2 2018 and has held it in 17 quarters since. The position peaked at $808K in Q3 2020. 47 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • Squarepoint held 247,799 shares of Ovid Therapeutics worth $617K as of Q3 2026.
  • Squarepoint bought 228,862 Ovid Therapeutics shares in Q3 2026, an estimated $599K.
  • Ovid Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3210 holding.
  • Squarepoint first reported a position in Ovid Therapeutics in Q2 2018 and has held it in 17 quarters since.
  • Squarepoint's Ovid Therapeutics position peaked at $808K in Q3 2020.
  • 47 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.